Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Celgene
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Burzynski Research Institute
Wake Forest University Health Sciences
NYU Langone Health
Northwestern University
M.D. Anderson Cancer Center
Northwestern University
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pediatric Brain Tumor Consortium
NYU Langone Health
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Eli Lilly and Company